US Patent

US8415342 — Besifloxacin ophthalmic composition for the treatment or control of infection

Method of Use · Assigned to Bausch and Lomb Inc · Expires 2030-11-07 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a besifloxacin ophthalmic composition for treating or controlling bacterial conjunctivitis caused by an antibiotic-resistant bacterium.

USPTO Abstract

A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.

Drugs covered by this patent

besifloxacin-hydrochloride (BESIFLOXACIN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-80`	—	besifloxacin-hydrochloride

Patent Metadata

Patent number: US8415342
Jurisdiction: US
Classification: Method of Use
Expires: 2030-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Bausch and Lomb Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.